The DOI matches its Crossref record; 442 of the 442 references it cites were found in a registry or an index.
Broad targeting of resistance to apoptosis in cancer
Open accessAbstract
Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–442 of 442
Hasim, A., Ma, H., Sheyhidin, I., Zhang, L., & Abudula, A. (2011) · PubMed · Cited by 33
The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway
García‐Caballero, M., Cañedo, L. M., Fernández-Medarde, A., Medina, M. Á., & Quesada, A. R. (2014) · Marine Drugs · doi:10.3390/md12010279 · Cited by 33
Etxebarria, A., Landeta, O., Antonsson, B. E., & Basáñez, G. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.003 · Cited by 33
Tripchlorolide induces cell death in lung cancer cells by autophagy
Chen, L., LIU, Q., Huang, Z., Wu, F., Li, Z., Chen, X., & Lin, T. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1278 · Cited by 33
Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT
Moon, D., Kim, M.-O., Choi, Y. H., Lee, H. G., Kim, N. D., & Kim, G. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.08.029 · Cited by 32
Breast cancer and cancer stem cells: a mini-review.
Filipová, A., Seifrtová, M., Mokrý, J., Dvořák, J., Řezáčová, M., Filip, S., & Garcia, D. D. (2014) · PubMed · doi:10.1700/1636.17886 · Cited by 31
Zhao, F., Huang, W., Tamgue, O., Zhang, B., Han, Y., Clotaire, D. Z. J., Wang, C., Chang, H., Luo, H., Ren, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080784 · Cited by 31
Novel agents for the treatment of chronic lymphocytic leukemia.
Abou-Nassar, K., & Brown, J. R. (2010) · PubMed · Cited by 31
The dynamics of karyopherin-mediated nuclear transport
Marelli, M., Dilworth, D. J., Wozniak, R. W., & Aitchison, J. D. (2001) · Biochemistry and Cell Biology · doi:10.1139/o01-149 · Cited by 30
Giampietri, C., Petrungaro, S., Padula, F., D’Alessio, A., Marini, E. S., Facchiano, A., Filippini, A., & Ziparo, E. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0752-z · Cited by 30
Edmond, V., Brambilla, C., Brambilla, E. M., Gazzéri, S., & Eymin, B. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15825 · Cited by 30
Haste, N. M., Farnaes, L., Perera, V. R., Fenical, W., Nizet, V., & Hensler, M. E. (2011) · Marine Drugs · doi:10.3390/md9040680 · Cited by 29
Nana-Sinkam, S. P., & Croce, C. M. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.09.007 · Cited by 29
Huq, F., Yu, J., Beale, P. J., Chan, C., Arzuman, L., Nessa, M. U., & Mazumder, M. E. H. (2014) · PubMed · Cited by 29
Härdtner, C., Multhoff, G., Falk, W., & Radons, J. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.03.039 · Cited by 28
Cleveland, J. L. (2008) · Biologics · doi:10.2147/btt.s1840 · Cited by 28
Coley, H. M., Safuwan, N. A. M., Chivers, P., Papacharalbous, E., Giannopoulos, T., Butler-Manuel, S. A., Madhuri, T. K., Lovell, D. P., & Crook, T. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.566 · Cited by 26
Self-citationBruel, A., Karsenty, E., Schmid, M., McDonnell, T. J., & Lanotte, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3594 · Cited by 25
Enhancement of cisplatin cytotoxicity by benzyl isothiocyanate in HL-60 cells
Lee, Y., Kim, Y. J., Choi, Y. J., Lee, J. W., Lee, S., & Chung, H. W. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.04.014 · Cited by 25
Sha, W., Olesch, C., Hanaka, H., Rådmark, O., Weigert, A., & Brüne, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.28181 · Cited by 24
Gonçalves, A. M. M. N., Lima, A. D., Barbosa, M. D. S., de Camargos, L. F., de Oliveira, J. T., Barbosa, C. D. S., Villar, J. A. F. P., Costa, A. D. S., da Silva, I. V. G., Silva, L., et al. (2014) · Marine Drugs · doi:10.3390/md12084361 · Cited by 24
Johnson, V., Cooper, I. R., Jenkins, J. R., & Chow, S. C. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4557 · Cited by 24
Zhu, S., Yao, F., Li, W.-H., Wan, J., Zhang, Y., Tang, Z., Khan, S. S., Wang, C.-H., & Sun, S.-R. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.10.5687 · Cited by 24
Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins
Tomic, J., McCaw, L., Li, Y., Hough, M. R., Ben‐David, Y., Moffat, J., & Spaner, D. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.04.004 · Cited by 24
Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer
Restall, I. J., & Lorimer, I. A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011076 · Cited by 23
2-Deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose
Qin, J.-Z., Xin, H., & Nickoloff, B. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.054 · Cited by 23
Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas
Mo, J., Sun, B., Zhao, X., Gu, Q., Dong, X., Liu, Z., Ma, Y., Zhao, N., Tang, R., Liu, Y., et al. (2013) · Pathology - Research and Practice · doi:10.1016/j.prp.2013.07.004 · Cited by 23
Breast Cancer and Cancer Stem Cells: A Mini-Review
Filipová, A., Seifrtová, M., Mokrý, J., Dvořák, J., Řezáčová, M., Filip, S., & Garcia, D. D. (2014) · Tumori Journal · doi:10.1177/1636.17886 · Cited by 23
Quality of life in patients with K‐RAS wild‐type colorectal cancer
Ringash, J. G., Au, H., Siu, L. L., Shapiro, J. D., Jonker, D. J., Zalcberg, J. R., Moore, M. J., Strickland, A. H., Kotb, R. R., Jeffery, M., et al. (2013) · Cancer · doi:10.1002/cncr.28410 · Cited by 22
Cytostatic drug treatment causes seeding of gene promoter methylation
Bredberg, A. C. A., & Bodmer, W. F. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.003 · Cited by 19
Busacca, S., Chacko, A. D., Klampatsa, A., Arthur, K., Sheaff, M. T., Gunasekharan, V., Gorski, J. J., El‐Tanani, M., Broaddus, V. C., Gaudino, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065489 · Cited by 19
Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors
Mayer, P., Harjung, A., Breinig, M., Fischer, L., Ehemann, V., Malz, M., Scherübl, H., Britsch, S., Werner, J., Kern, M. A., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0227 · Cited by 18
Regulation of c-Raf-1: therapeutic implications.
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2003) · PubMed · Cited by 18
Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer
Anai, S., Sakamoto, N., Sakai, Y., Tanaka, M., Porvasnik, S., Urbanek, C., Cao, W., Goodison, S., & Rosser, C. J. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.04.009 · Cited by 17
Sensitization of Glioma Cells by X-Linked Inhibitor of Apoptosis Protein Knockdown
Lopez, P. L. C., Filippi‐Chiela, E. C., Silva, A. O., Cordero, E. A. A., Garcia‐Santos, D., Pelegrini, A. L., Reder, G. M., Barbieri, N. L., & Lenz, G. (2012) · Oncology · doi:10.1159/000337978 · Cited by 16
Epithelial-mesenchymal transition and pancreatic cancer progression
Dangi-Garimella, S. Y., Krantz, S. B., Shields, M. A., Grippo, P. J., & Munshi, H. G. (2012) · Europe PMC (PubMed Central) · Cited by 16
Napyradiomycins CNQ525.510B and A80915C target the Hsp90 paralogue Grp94
Farnaes, L., Clair, J. J. L., & Fenical, W. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41355a · Cited by 14
Kondo, S., Kondo, Y., Daido, S., & Iwado, E. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1087 · Cited by 14
Manipulating chemoattractant and receptor genes.
Le, Y., Cui, Y., Iribarren, P., Ying, G., & Wang, J. M. (2002) · PubMed · Cited by 13
Yin, Y., Chen, X., ZHANG, C.-D., Liu, P., DUAN, Y.-R., Fan, Y., WU, Z.-W., FU, G.-F., WANG, J.-J., & XU, G.-X. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1691 · Cited by 12
Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention
Kumar, N. B. (2013) · Translational Medicine · doi:10.4172/2161-1025.s2-005 · Cited by 10
Self-citationKumar, N. B., Crocker, T., & Smith, T. (2012) · Journal of Clinical Trials · doi:10.4172/jctr.1000105 · Cited by 9
Self-citation
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Self-citationRegulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Efimova, I., Catanzaro, E., Van der Meeren, L., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001369 · Cited by 520
Self-citationOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Metadata
- Authors
- Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., Yang, H., Samadi, A. K., Russo, G. L., Spagnuolo, C., Ray, S. K., Chakrabarti, M., Morre, J. D., Coley, H. M., Honoki, K., Fujii, H., Georgakilas, A. G., Amedei, A., Niccolai, E., Amin, A., Ashraf, S. S., Helferich, W. G., Yang, X., Boosani, C. S., Guha, G., Bhakta, D., Ciriolo, M. R., Aquilano, K., Chen, S., Mohammed, S. I., Keith, W. N., Bilsland, A., Halicka, D., Nowsheen, S., & Azmi, A. S.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 35
- Pages
- S78-S103
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2072860434
- Cited by
- 864
- References
- 442
- FWCI
- 17.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.